Exam 2: NSAIDs and Opioids Flashcards
Receptor most responsible for transmission of pain signals:
TRPV1
Function of B2 receptor:
Enhances TRPV1 activity
Function of prostanoid receptor:
Aids in depolarization of pain fiber via enhancement of voltage-gated Na+ channel
Function of opioid, cannabinoid, and norepi receptors:
Hyperpolarization of pain fibers via ↑ K+ retention
B2 receptors activated by:
Bradykinin
Laminae of Αδ fibers:
I, II, III, V
Laminae of C fibers:
I, II
Laminae of substantia gelatinosa:
II, III
Substantia gelatinosa is important because:
Richly populated with opioid peptides, receptors
Inhibitory interneurons
Area of the brain that descends neurons into substantia gelatinosa:
Nucleus raphe magnus
Opioid action in the brain:
Pre- and postsynaptically activate descending inhibitory pathways
Opioid action in the SC:
Directly on the dorsal horn
Opioid action in the periphery:
Peripheral terminals of nociceptive neurons
Opioid effect on pain perception:
Changes tolerance of pain without necessarily changing ability to perceive pain
Opioid effect on physiological response to pain:
Reduces neuroendocrine response:
SNS activation
Cortisol
Norepi release
Opioid use in anesthesia:
Attenuate SNS response to stimuli
Adjunct to IAs
Can be sole anesthetic (cardiac/trauma)
Periop/postop pain mgmt
Unique characteristics of opioids vs. other analgesics:
No max dose or ceiling effect
Tolerance develops with chronic use
Produces analgesia without loss of touch/proprioception/consciousness
Ex. of naturally occuring opioids:
Morphine, codeine
Ex. of semisynthetic analogs of morphine:
Heroin, dihydromorphone
Classifications of opioids:
Full agonist
Partial agonist
Mixed agonist/antagonist
Antagonist
MoA (presynaptic) of opioids:
Inhibits release of excitatory NTs (ACh, dopamine, norepi, substance P)
MoA (postsynaptic) of opioids:
Directly decreases neurotransmission
↑ K+ conductance: hyperpolarization
↓ Ca2+ channel activity: ↓ NT release
Modulation of phospholipase C
↓ cAMP
Opioid receptors:
Mu
Kappa
Delta
Mu-1 receptor locations:
Supraspinal*
Spinal
Peripheral
Effects of mu-1 receptor activation:
Euphoria Miosis Bradycardia (good in adults, not in peds) Urinary retention Hypothermia
Effects of mu-2 receptor activation:
Hypoventilation
Physical dependence
Constipation
Mu-2 receptor locations:
Spinal*
Some supraspinal
Kappa receptor locations:
Supraspinal*
Spinal*
Peripheral
Effects of kappa receptor activation:
Dysphoria
Sedation
Miosis
Diuresis
Drugs that work on kappa receptors:
Dynorphins
Opioid agonist-antagonists
Delta receptor locations:
Peripheral*
Supraspinal
Spinal
Effects of delta receptor activation:
Hypoventilation
Constipation
Urinary retention
Drugs that work on delta receptors:
Enkephalins
Two mutations to 6q24-q25 that can affect response to opioids:
Nucleotide 118 (10-20%) Nucleotide 17 (1-10%)
CYP450 mutation that alters metabolism of some opioids:
CYP2D6
Unpredictable PK and t1/2 of codeine, oxycodone, hydrocodone, and methadone
Drug least likely to be impacted by genetic variability:
Fentanyl
Ultra-rapid metabolizers at increased risk of:
PONV
and other side effects
CV effects of opioids:
Minimal impairment when used alone
Dose dependent bradycardia (vagal stimulation, direct SA/AV node depression)
Vasodilation/↓SVR (impairment of SNS tone, leading to ↓CO, ↓BP esp. with hypovolemia)
CV effects of morphine and meperidine:
Dose dependent histamine release
Bronchospasm
↓SVR, ↓BP
Exception to bradycardia effect of opioids:
Meperidine; causes tachycardia with direct myocardial depression
CNS effects of opioids:
Analgesia Euphoria Drowsiness Miosis Nausea No amnesia Decrease ICP and CBF - only if no hypoventilation though
Renal, GI, liver effects of opioids:
↑ tone of ureter and detrusor tone leads to urgency without ability to void
↓ catecholamine and cortisol release
Sphincter of Oddi spasm, ↑ biliary pressure
GI smooth muscle spasm
Constipation
N/V
How can opioids cause angina-mimicking pain?
Sphincter of Oddi/gallbladder spasms
Means by which opioids cause N/V:
↓ gastric emptying
Stimulation of CTZ on floor of 4th ventricle
Describe pruritis from opioids:
Unknown cause, likely histamine release
Primarily on face, esp. nose
Skeletal muscle effects of opioids:
Rigidity in chest, abdomen, jaw, extremities (esp. large, rapid doses)
Difficult/impossible ventilation, ↑ airway pressure
Glottic rigidity/closure
Opioids particularly prone to causing rigidity:
Fentanyl
Sufentanil
Hydromorphone
Ventilatory effects of opioids:
Dose dependent respiratory depression (small doses: ↑ Vt, ↓ RR with overall ↓ MV; large doses: ↓ Vt and RR)
↓ chest wall compliance
Cough suppression
Constriction of laryngeal/pharyngeal muscles
↓ response to hypercarbia, hypoxia
Morphine/meperidine: histamine-related bronchospasm
Opioid-induced changes in ventilatory response curve:
Reduced slope and shifted to right
Indications for PO morphine:
Severe acute pain: IM/IV
Chronic/cancer pain: PO
PK of PO morphine:
Considerable first pass effect
Et1/2: 3-4 hrs
Active metabolite
Indications for PO codeine:
Mild pain
Cough (lower dose)
PK of PO codeine:
Et1/2: 3hrs
Prodrug; 10% converted by CYP2D6 to active form, morphine
Racial groups prone to missing CYP2D6:
Caucasian (10%)
Asian (30%)
Indications for PO hydrocodone:
Chronic pain
Post-op pain relief
Formulation of PO hydrocodone:
Always combined with APAP, ASA, ibuprofen, or antihistamine
Indications for PO oxycodone:
Moderate to severe pain
Chronic pain
Post-op pain
Formulation of PO oxycodone:
Alone
Sustained-release
Combined with APAP or ASA
Patient population for which oxycodone and methadone are safer:
Renal - no active metabolites
Indications for PO methadone:
Chronic pain syndrome
Opioid addiction
PK of PO methadone:
Et1/2: 8-59 or 13-100 hrs
No active metabolites
Dosing schedule for methadone:
QD for addiction
BID/TID for pain
Order of events when tolerance develops to opioids:
↓ adverse effects
↓ duration of analgesia
↓ effectiveness of each dose
When switching from one opioid to another:
Start with half or less of equianalgesic dose
Side effect of opioids that pts do not develop tolerance to:
Constipation
Breakthrough pain dose for opioids:
10-15% of total daily dose in immediate release form
Receptors that provide neuraxial analgesia from opioids:
Mu receptors in substantia gelatinosa
Cephalad movement of opioid in CSF limited by:
Lipid solubility
Fentanyl (highly lipid soluble) limited in migration
Morphine (less lipid soluble) will remain in CSF and migrate to cephalic region
Epidural vs. spinal opioid dose:
Epidural is 5-10x higher dose
Indications for non-opioid analgesics:
Mild to moderate pain
Ceiling effect dose of ASA and APAP:
650-1300mg
MoA of acetaminophen:
Central anti-prostaglandin effect
Blockade of NMDA receptor in CNS
Blockade of substance P in spinal cord
Weak anti-inflammatory behavior; no peripheral activity
Dosage of acetaminophen:
PO: 325-650mg q4-6hr
IV: 1gm over 15 min infusion q4-6hr
PK of acetaminophen:
Conjugated/hydroxylated to inactive metabolites
Very little excreted unchanged by kidneys
Overdose of acetaminophen:
Serious or fatal hepatic injury when glutathione overwhelmed by acetaminophen
↑ risk of toxicity in ETOH, isoniazid use
Tx with acetylcysteine to sub for glutathione
Renal toxicity from acetaminophen:
Metabolites accumulate in renal papillae and cause renal cell necrosis
Relatively low risk
Three pathways of arachadonic acid metabolism:
Cyclooxygenase
Lipoxygenase
Epoxygenase
Cyclooxygenase metabolism of arachadonic acid leads to formation of:
Prostaglandins
Prostacylcin
Thromboxanes
Lipoxygenase metabolism of arachadonic acid leads to formation of:
Leukotrienes
Lipoxins
COX-1 prostaglandins serve in:
Gastric protection
Hemostasis
Renal function
COX-2 prostaglandins serve in:
Pain
Inflammation
Fever
Indications for aspirin:
Mild to moderate pain
Fever
MI/stroke prevention
Duration of action of aspirin:
Life of platelet; 8-10 days
Irreversible!
System side effects of aspirin:
Prolonged bleeding but no renal disease Can ↑ LFTs (reversible) Can potentiate asthma GI bleeding/PUD CNS stimulation
Dosage of aspirin:
Analgesic: 325-650mg
Anti-inflammatory: 1000mg (3-5g/day)
PK of aspirin:
Hepatic clearance
Active metabolite
Et1/2: 15-20 min for ASA, 2-3 hrs for salicylic acid
S/s of ASA overdose:
Metabolic acidosis
Tinnitis
Efficacy of NSAIDs:
More effective than ASA/APAP
Equal or greater than usual doses of opioid+APAP
Anti-inflammatory
MoA of NSAIDs:
Blocks conversion of arachidonic acid to prostaglandins –> analgesic, anti-inflammatory, antipyretic
PK of NSAIDs:
Weak acids, well absorbed Highly protein bound (>95%) Small Vd Extensively metabolized Excreted in urine Et1/2 varies: < 6 to > 12 hrs
Side effects of NSAIDs:
Asthma/anaphyalctoid rxns
Plt inhibition (reversible)
Hepatic injury, aseptic meningitis (rare)
Pregnancy and NSAIDs:
Avoid in third trimester d/t premature closure of DA
COX inhibition in the peri-op period can cause:
Renal injury
Gastric ulcers
Bleeding
Impaired bone healing
GI adverse effects of NSAIDs:
Dyspepsia GI bleeding PUD ↑ acid production ↓ mucus production, gastric blood flow Irritation due to trapping in mucosal cells
Risk factors for GI effects with NSAIDs:
High dose Long-term use Hx of ulcer/GIB ETOH Elderly *Corticosteroids
Low-risk NSAIDs:
Low-dose ibuprofen, naproxen
Etodolac
Sulindac
Celecoxib
High-risk NSAIDs:
Tolmetin Piroxicam Aspirin Indomethacin Ketorolac
Renal side effects of NSAIDs:
↓ synthesis of renal vasodilator PGE2
↓ renal blood flow –> fluid/Na+ retention –> renal failure/hypertension (this is only in susceptible populations)
Drug interactions with NSAIDs:
Displaces other protein-bound drugs (warfarin, phenytoin, sulfonamides, digoxin)
↓ effect of diuretics, β blockers, ACEIs
↑ lithium levels
Probencid ↑ levels of NSAIDs
Only IV NSAID in US:
Ketorolac
PK of ketorolac:
Onset 10 min (IV) Et1/2: 5 hrs Duration: 6-8 hrs 99% protein-bound Conjugated in liver
Dosing of ketorolac:
30mg IV q6hr
Daily max 120mg
1/2 dose for elderly
Only selective NSAID:
Celecoxib
Dosing of celecoxib:
< 200mg/day
Adjuvant analgesics:
Antidepressants/anticonvulsants for neuropathic pain
Hydroxyzine for cancer and post-op pain (plus ↓ PONV)
Corticosteroids for inflammatory disease of tumor infiltration of nerves
Topical analgesics